Derrell D. Porter

Director at Biosortia Microbiomics

Founder & CEO at Cellevolve Bio. Prior to Cellevolve, Dr. Porter was SVP and Head of Commercial at Atara Biotherapeutics, Inc. Prior to joining Atara, he was a Vice President with Gilead Sciences, where he was responsible for corporate strategy, long term commercial planning, and global launch preparation for pipeline compounds in all of Gilead’s therapeutic areas – Oncology, HIV, Liver Diseases (HCV, HBV, and NASH), CV, and Inflammatory Disorders. With a successful biopharmaceutical career spanning 15+ years, Dr. Porter is a seasoned executive with experience running businesses in the US and Europe, corporate development and global marketing, as well as management consulting, including AbbVie and Amgen. He began his career at McKinsey & Company in Los Angeles as part of the West Coast Health Care Practice. Dr. Porter holds an MD from the University of Pennsylvania, where he was a Twenty First Century Scholar, an MBA from The Wharton School and a bachelor’s degree in neuroscience from UCLA.

Timeline

  • Director

    Current role